Cellular aspect of neuroinflammation in Guillain-Barré syndrome: A key to a new therapeutic option?;Aspects cellulaires de la neuroinflammation au cours du syndrome de Guillain-Barré: Une clé pour une nouvelle voie thérapeutique?

Revue Neurologique

Volumn 158, Issue 1, 2002, Pages 15-27

  Creange A ^a   Sharshar, T ^a,b   Raphael J C ^a,b   Gherardi, R ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CELL ADHESION MOLECULE; CYTOKINE; GELATINASE B; IMMUNOGLOBULIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC NEUROPATHY; ANTIGEN PRESENTATION; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; CYTOTOXICITY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; PLASMAPHERESIS; REVIEW;

GUILLAIN-BARRE SYNDROME; HUMANS; INTERFERON-BETA;

EID: 17744405695     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (143)

1. Suppression of experimental allergic neuritis by an antibody to the intercellular adhesion molecule ICAM-1
2. The inflammatory lesion in idiopathic polyneuritis
3. IFN-beta interferes with the differentiation of dendritic cells from peripheral blood mononuclear cells: Selective inhibition of CD40-dependent interleukin-12 secretion
4. Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis
5. Recombinant interferon-γ increases HLA-DR synthesis and expression
6. Interferon-γ secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon-β therapy
7. Signals and receptors involved in recruitment of inflammatory cells
8. Decreases in T-cell tumor necrosis factor a binding with interferon beta treatment in patients with multiple sclerosis
9. Plasma exchange morbidity in Guillain-Barré syndrome: Results from the french prospective, randomized, multicenter study
10. Complications of intravenous immune globulin treatment in neurologic disease
11. Demyelination in vitro by Guillain-Barré syndrome and other human serum
12. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: A macro-patch-clamp study
13. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI
14. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b
15. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
16. Repeated vital capacity measurement as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barré Syndrome
17. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome
18. Tissue-specific homing receptor mediates lymphocyte adhesion to cytokine-stimulated lymph node high endothelial venule cells
19. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy
20. Immune dysregulation in TGF-β1 deficient mice
21. Interferon-beta not only inhibits interleukin-1β and tumor necrosis factor-a but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells
22. Effects of beta-IFN-1β treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: An in vivo and in vitro study
23. Circulating transforming growth factor-beta 1 (TGF-β1) in Guillain-Barré syndrome: Decreased levels in the early course and increase with motor function
24. Circulating tumor necrosis factor (TNF)-alpha and soluble TNF- alpha receptors in patients with Guillain-Barre syndrome
25. Inhibition of the adhesion step of leukodiapedesis: A critical event in the recovery of Guillain-Barré syndrome associated with accumulation of proteolytically active lymphocytes in blood
26. Treatment of Guillain-Barré syndrome with interferon-beta
27. Matrix metalloproteinase-9 is increased and correlates with disease severity in Guillain-Barré syndrome
28. Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells
29. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines
30. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b
31. Interferon beta normalizes suppressor cell function in dysimmune neuropathies
32. Interferons
33. Interferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells
34. The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat
35. Passive transfer studies in Guillain-Barré polyneuropathy
36. Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids
37. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-β1
38. Increase CD80+ B cells in active multiple sclerosis and reversal by interferon β-1b therapy
39. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy
40. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-α 2a
41. Phrenic nerve conduction time in Guillain-Barré syndrome
42. Macrophage systems in peripheral nerves. A review
43. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome
44. Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome
45. Randomized trial of interferon β1a in chronic inflammatory demyelinating polyradiculoneuropathy
46. Acute motor axonal neuropathy: An antibody-mediated attack on axolemma
47. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections
48. Demyelination induced by serum from patients with Guillain-Barré syndrome
49. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuroapthy: Comparison with other neurological diseases of presumed immunopathogenesis
50. Pathogenesis of inflammatory demyelination: Implications for therapy
51. Immunopathogenesis and treatment of the Guillain-Barré syndrome - Part I
52. Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies
53. The role of interféron-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system
54. Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies
55. Selective inhibition of human glial inducible nitric oxide synthase by interferon-beta: Implications for multiple sclerosis
56. Matrix metalloproteinase expression during experimental autoimmune neuritis
57. Type I interferons enhance production of IFN-gamma by NK cells
58. Interferon-b downregulates interferon-g-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells
59. Interferon beta-1b is effective in relapsing- remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double blind, placebo-controlled trial
60. Serum antibodies to gangliosides in Guillain-Barré syndrome
61. IFN induction and associated changes in splenic leukocyte distribution
62. Down-regulation of interferon-g-induced class II expression on human glioma cells by recombinant interferon-b: Effects of dosage treatment schedule
63. Therapeutic effect of transforming growth factor-b2 on actively induced EAN but not adoptive transfer EAN
64. Interferon β in multiple sclerosis: Is IL-12 suppression the key?
65. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing- remitting multiple sclerosis
66. Transforming growth factor-β1 in experimental autoimmune neuritis. Cellular localization and time course
67. Virus-induced interferon alpha/beta (IFN-alpha/beta) production by T cells and by Th1 and Th2 helper T cell clones: A study of the immunoregulatory actions of IFN-gamma versus IFN-alpha/beta on functions of different T cell populations
68. Effect of interferon on thoraci duct lymphocyte output: Induction with either poly 1: Poly C or vaccinia virus
69. Anti-peripheral nerve myelin antibodies in Guillain-Barré syndrome bind a neutral glycolipid of peripheral myelin and cross-react with Forssman-antigen
70. Interferon beta induces T-helper 2 immune deviation in MS
71. Interferon-β1a in chronic inflammatory demyelinating polyneuropathy
72. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome
73. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis
74. Recent advances in immunology in multiple sclerosis
75. IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia
76. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer
77. Chronic motor neuropathies: Response to interferon-beta 1a after failure of conventional therapies
78. Plasmapheresis and Guillain-Barré syndrome: Analysis of prognostic factors and the effect of plasmapheresis
79. Human recombinant interferon-beta influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors
80. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development
81. IFN-gamma inhibits activation-induced expression of E- and P-selectin on endothelial cells
82. Activité démyélinisante sérique et syndrome de Guillain-Barré: Effet favorable des échanges plasmatiques
83. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering
84. The matrix metalloproteinases and their inhibitors
85. Characterization of campylobacter jejuni isolates from patients with Guillain-Barré syndrome
86. Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies
87. Interferon β decreases T cell activation and interferon gamma production in multiple sclerosis
88. In vivo effects of sera from Guillain-Barré subgroups: An electrophysiological and histological study on rat nerves
89. Immunomodulatory effects of interferon-beta-1b in vivo: Induction of the expression of transforming growth factor-beta1 and its receptor type II
90. Interferons in multiple sclerosis. A review of the evidence
91. Beta interferon prevents HLA class II antigen induction by gamma interferon in MS
92. Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis
93. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome
94. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
95. Leucocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein
96. Prise en charge d'un syndrome de Guillain-Barré
97. Comparaison de deux posologies d'immunoglobulines [IgIV] chez les patients présentant un syndrome de Guillain-Barré [SGB] et des contre-indications aux échanges plasmatiques. Résultats de la premibre première analyse intermédiaire
98. Le syndrome de Landry-Guillain-Barré. Etude des facteurs pronostiques dans 223 cas
99. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor
100. A combined inhibitor of matrix metalloproteinase activity and tumor necrosis factor-a processing attenuates experimental autoimmuneuritis
101. Campylobacter jejuni infection and Guillain-Barré syndrome
102. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells
103. Antagonism of interferon beta on interferon gamma: Inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients
104. Leukaemia inhibitory factor promotes the neuronal development of spinal cord precursors from the neural tube
105. T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis
106. Epidemiology
107. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta
108. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis
109. The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats
110. Nerve lesions induced by macrophage activation
111. In vivo demyelinating activity of serum from patients with Guillain-Barré syndrome
112. Immunological suppression by human CD8+ T cells is receptor dependent and HLA-DQ restricted
113. Tumor necrosis factor mediates myelin and oligodendrocytes damage in vitro
114. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination
115. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease
116. Potential role of transforming growth factor-b1 in terminating the immune response in patients with Guillain-Barré syndrome
117. Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo b-interferon
118. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
119. Pretreatment of astrocytes with interferonalpha/beta impairs interferon-gamma induction of nitric oxide synthase
120. Interferon beta-1b decreases the migration of T lymphocytes in vitro-effects on matrix metalloproteinase-9
121. Acute conduction block associated with experimental antiserum mediated demyelination of peripheral nerve
122. Appropriate number of plasma exchanges in Guillain-Barré syndrome
123. Plasmapheresis and acute Guillain-Barré syndrome
124. The prognosis and main prognostic indicators of Guillain-Barre syndrome. A multicentre prospective study of 297 patients
125. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease
126. Deactivation of macrophages by transforming growth factor-β
127. Treatment of multifocal motor neuropathy with interferon-β1A
128. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré Syndrome
129. Intravenous immunoglobulins and transforming growth factor beta
130. Antagonistic action of IFN-beta and IFN-gamma on high affinity Fc gamma receptor expression in healthy controls and multiple sclerosis patients
131. Oral administration of type I interferon β modulates the course of experimental allergic neuritis
132. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome
133. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
134. The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis
135. Rationale for immunotherapy in multiple sclerosis
136. Prognosis in Guillain-Barré syndrome
137. Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion
138. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action
139. Structure and localization of gangliosides
140. Penner's serotype 4 of campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope
141. Thalidomide prolongs experimental autoimmune neuritis in Lewis rats
142. Respiratory electrophysiological studies in Guillain-Barré syndrome
143. IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue